SPI is a wholly owned subsidiary of Sumitomo Corporation and is an integrated service company specializing in the area of pharmaceutical development and commercialization with 90 professional staffs at 5 locations including own API warehouse and analytical laboratory in Japan. SPI has a good track record in activities such as, exclusive agent of ATCC (the world's largest gene/cell bank for research) of the USA, supply of starting materials, intermediates and active pharmaceutical raw materials for pharmaceuticals, and intermediation/consultation services in license/co-research arrangements of promising drugs/diagnostics/technologies originating from domestic and foreign bio-ventures, pharmaceutical companies, universities and institutes.

MISSION

SPI contributes to the improvement of health and well-being and enriching lives.

As a leading corporation in the pharmaceutical as well as cosmetic industry, they are helping society maintain an active lifestyle even as they age, by providing efficacious and highly safe products with reliable supply chains.

SPI provides support to customers’ value creation through innovative thinking.

As a leading solutions provider in the medical, pharmaceutical and cosmetic industry, they support customers’ value creation by challenging their employees to engage in innovative problem-solving.

SPI is committed to improving the work environment and to respect and promote diversity.

They know that diversity among employees is one of their company’s greatest assets. They maintain continuous workplace improvement and put priority on recruitment and appointment of women.

Summit Pharmaceuticals International leverages the global network of the Sumitomo Corporation Group to provide high value-added services centered on the import and sale of APIs and research materials as a core business company of the group’s medical science business line.